Boston Scientific Corp.
BSX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$66.38B
Close$
Earnings Call Q3 2026
October 28, 2026 - AI Summary
Q3 performance missed guidance due to cyber incident (big negative):
- Organic sales +1.5% (vs guide +3% to +5%) and adjusted EPS $0.73 (-3% YoY) (vs guide $0.80–$0.82).
- Company estimates cyber incident reduced Q3 organic revenue growth by ~300 bps, including ~$150M top-line headwind and ~$0.07 negative EPS impact (lower sales + unfavorable manufacturing absorption and other costs).
- Ops restored after a 2-week outage; all operations back up as of Sept 8.
Q4 outlook also pressured by cyber + demand/inventory dynamics:
- Organic revenue guidance: -1% to -3%; adjusted EPS $0.77–$0.79.
- Expect 200–300 bps ongoing impact from cyber, as customers rebuild/normalize ordering and the company burns off elevated end-Q3 inventory levels.
- Full-year 2026 guidance reaffirmed/improved: organic revenue +4% (operational/FX described), EPS $3.16–$3.18.
2027 “trough” framing: growth and EPS expected to be challenged (mixed to negative):
- Management says 2027 will be the trough cycle year; however it will be challenging to grow sales and adjusted EPS in 2027 excluding the pending Penumbra acquisition.
- Key reasons: expected persistence of Q4 underlying business dynamics, especially EP and Watchman weakness, plus additional China price headwinds.
- Assumption is essentially no improvement vs current Watchman market conditions until evidence/label changes take effect, and an accelerated share erosion dynamic in EP until product/platform launches.
Exclusive for Stockcircle Pro members
Sign up
$91.92
100.6% upside
Current Fair Value
100.6% upsideUndervalued by 100.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $66.38 Billion |
|---|---|
| Enterprise Value | $78.85 Billion |
| Earnings per Share | $1.96 |
| Beta | 0.58 |
| Outstanding Shares | 1,448,700,000 |
Return
| Return on Equity | 14.05% |
|---|---|
| Return on Assets | 7.75% |
| Return on Invested Capital | 10.79% |
Valuation & Multiples
| P/E Ratio | 17.71 |
|---|---|
| PEG | -81.46 |
| Price to Sales | 3.27 |
| Price to Book Ratio | 2.7 |
| Enterprise Value to Revenue | 3.72 |
| Enterprise Value to EBIT | 18.84 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.52 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 28, 2026
EPS Estimate
$0.73
Consensus analyst estimateRevenue Estimate
$5.09 B
Consensus analyst estimateNext Earnings Call
Expected Date
February 3, 2027
EPS Estimate
$0.79
Consensus analyst estimateRevenue Estimate
$5.20 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.56, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.5649▲ 13.27% |
|---|---|
| Total Calls | 271,900▼ 99.31% |
| Total Puts | 153,600▼ 99.10% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.10%▼ 87.52% |
|---|---|
| Total Invested | $1.99B▼ 96.55% |
| Investors Holding | 525▼ 1055.00% |
About Boston Scientific Corporation
45,000 employees
CEO: Michael F. Mahoney
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The com...